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MLC tracking for lung SABR is feasible, efficient and delivers high-precision target
dose and lower normal tissue dose
Abstract
Background and purpose: The purpose of this work is to present the clinical experience from the first-inhuman trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy
(SABR) of lung lesions. Methods and materials: Seventeen patients with stage 1 non-small cell lung
cancer (NSCLC) or lung metastases were included in a study of electromagnetic transponder–guided
MLC tracking for SABR (NCT02514512). Patients had electromagnetic transponders inserted near the
tumor. An MLC tracking SABR plan was generated with planning target volume (PTV) expanded 5 mm
from the end-exhale gross tumor volume (GTV). A clinically approved comparator plan was generated
with PTV expanded 5 mm from a 4DCT-derived internal target volume (ITV). Treatment was delivered
using a standard linear accelerator to continuously adapt the MLC based on transponder motion. Treated
volumes and reconstructed delivered dose were compared between MLC tracking and comparator ITVbased treatment. Results: All seventeen patients were successfully treated with MLC tracking (70
successful fractions). MLC tracking treatment delivery time averaged 8 minutes. The time from the start
of CBCT to the end of treatment averaged 22 minutes. The MLC tracking PTV for 16/17 patients was
smaller than the ITV-based PTV (range −1.6% to 44% reduction, or −0.6 to 18 cc). Reductions in mean
lung dose (27 cGy) and V20Gy (50 cc) were statistically significant (p < 0.02). Reconstruction of treatment
doses confirmed a statistically significant improvement in delivered GTV D98% (p < 0.05) from planned
dose compared with the ITV-based plans. Conclusion: The first treatments with lung MLC tracking have
been successfully performed in seventeen SABR patients. MLC tracking for lung SABR is feasible, efficient
and delivers high-precision target dose and lower normal tissue dose.
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Abstract: Group A Streptococcus (GAS) causes 700 million infections and accounts for half a million
deaths per year. Antibiotic treatment failure rates of 20–40% have been observed. The role host cell
glycans play in GAS biofilm formation in the context of GAS pharyngitis and subsequent antibiotic
treatment failure has not been previously investigated. GAS serotype M12 GAS biofilms were assessed
for biofilm formation on Detroit 562 pharyngeal cell monolayers following enzymatic removal of all
N-linked glycans from pharyngeal cells with PNGase F. Removal of N-linked glycans resulted in an
increase in biofilm biomass compared to untreated controls. Further investigation into the removal of
terminal mannose and sialic acid residues with α1-6 mannosidase and the broad specificity sialidase
(Sialidase A) also found that biofilm biomass increased significantly when compared to untreated
controls. Increases in biofilm biomass were associated with increased production of extracellular
polymeric substances (EPS). Furthermore, it was found that M12 GAS biofilms grown on untreated
pharyngeal monolayers exhibited a 2500-fold increase in penicillin tolerance compared to planktonic
GAS. Pre-treatment of monolayers with exoglycosidases resulted in a further doubling of penicillin
tolerance in resultant biofilms. Lastly, an additional eight GAS emm-types were assessed for biofilm
formation in response to terminal mannose and sialic acid residue removal. As seen for M12, biofilm
biomass on monolayers increased following removal of terminal mannose and sialic acid residues.
Collectively, these data demonstrate that pharyngeal cell surface glycan structures directly impact
GAS biofilm formation in a strain and glycan specific fashion.
Keywords: group A Streptococcus; Streptococcus pyogenes; biofilm; glycans; antibiotics; penicillin; EPS

1. Introduction
Group A Streptococcus (Streptococcus pyogenes; GAS) is a Gram-positive human pathogen
responsible for a variety of infections. GAS pharyngitis is the most common disease state, with global
incidence estimated at 600 million cases per year [1]. Currently, penicillin remains the antibiotic
of choice for treating GAS infections, with no reports of penicillin resistance among clinical GAS
isolates. However, antibiotic treatment failure has been well-documented at rates of 20–40% for
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GAS pharyngitis [2–4]. Biofilms enable bacteria to survive and tolerate both host immunity and
antimicrobial treatment. As a result, biofilm-associated infections are oftentimes chronic and recurrent,
and particularly difficult to clear and treat [3–5]. Recently, it has been proposed that GAS may form
biofilms, contributing to antibiotic treatment failure [3]. There is evidence of bacterial biofilm formation
in human tonsils [6], and in a study of patients suffering from recurrent GAS pharyngo-tonsillitis,
the presence of GAS biofilms in tonsillar crypts was identified in all 30 patients [7]. Furthermore, in a
study assessing GAS isolated from pharyngitis patients non-responsive to antibiotics, all 99 GAS
isolates demonstrated biofilm-forming ability in vivo, with 60% of these displaying increased penicillin
tolerance once in the biofilm phenotype [3]. However, most of these studies utilized abiotic surfaces
(glass, plastic, polystyrene) and very few incorporated surface coating with extracellular matrix
components such as fibronectin, fibrinogen, laminin, or collagen [8–11]. The host cell surface is integral
in initial host-pathogen interactions, bacterial cell adherence, and subsequent biofilm formation [12].
Thus, there is a need to better understand the role of host cell surface receptors in GAS biofilm formation.
Glycans are carbohydrates present on more than half of all human proteins, with their ubiquitous
presence in mucosal fluid, on secreted molecules, immune cells, and a variety of epithelial cell
surfaces, making glycosylation one of the most common post-translational modifications [13,14].
Glycans are the initial point of contact with the host for many bacteria, mediating attachment
and colonization, and can consequently facilitate infection and disease. Several human bacterial
pathogens such as Pseudomonas aeruginosa, Enterococcus faecalis, Helicobacter pylori, Streptococcus gordonii,
and Streptococcus pneumoniae have proven adept at adhering to and utilizing glycan structures for
pathogenesis [15–19]. Bacterial modification of host glycan structures enables binding to otherwise
inaccessible host receptors for adherence, modulation of host immune molecules, acquisition
of carbohydrate substrates for non-glucose fermentation, facilitation of interspecies competition,
and promotion of biofilm formation [15–19]. An example of a well-characterized glycan-utilizing
system is the NanA neuraminidase of S. pneumoniae, which cleaves off terminal sialic acid residues
from glycans. NanA has been shown to be particularly active during cluster formation and biofilm
maturation in vivo [20]. Another study found increased S. pneumoniae biofilm formation was seen only
for biofilms exposed to sialic acid, but not in the presence of other glycans [21].
The utilization of glycans by GAS remains poorly understood, despite GAS possessing an array of
adhesins capable of binding structures on the richly glycosylated epithelial surfaces and in the fluids of
the oropharynx. Studies to date have focused on planktonic GAS-host glycan interactions in the context
of the M protein, a major surface-expressed protein which has a role in the adherence of GAS to host
tissues [22–25]. Investigation of the ability of M proteins from 49 GAS serotypes to associate with various
pharyngeal- and dermal-associated glycosaminoglycans (GAGs) revealed that GAGs mediated GAS
adhesion to human cells in an M protein-dependent manner [23]. Recently, M1 GAS was shown to bind
glycans via the M protein, including the ABO(H) blood group antigens, which are oligosaccharides
abundant on the epithelia of most individuals, including the pharynx [24]. Similar trends were
observed in two other prevalent GAS M-types, M3 and M12 [25]. Interestingly, this study showed
that modification of the cell surface glycome via treatment with a range of exoglycosidases altered
GAS-host cell interactions [25]. Taken together, these findings further highlight the role of glycans in
mediating GAS adherence.
Whilst the role of host glycans in GAS adherence has been investigated, their role in GAS biofilm
formation has yet to be examined. Investigation of glyco-interactions at the GAS-tissue interface
in the context of biofilms will enhance our understanding of GAS biofilms and GAS pathogenesis.
Consequently, findings of such studies may inform and support the development of novel anti-biofilm
strategies as well as biofilm-specific antibiotic treatments. Herein, we examine the role of human
pharyngeal N-glycans in M12 GAS biofilm formation and subsequent penicillin tolerance.
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1A). In the absence of N-linked glycans, planktonic M12 GAS displayed a significant decrease
(Figure(Figure
1A). In
the absence of N-linked glycans, planktonic M12 GAS displayed a significant decrease
in initial adherence (p ≤ 0.05) when compared to adherence to untreated cells (Figure 1B). Despite a
in initial adherence (p ≤ 0.05) when compared to adherence to untreated cells (Figure 1B). Despite a
reduction in initial GAS adherence, M12 GAS biofilm biomass increased significantly (p ≤ 0.0001) on
reduction
in initial GAS adherence, M12 GAS biofilm biomass increased significantly (p ≤ 0.0001) on the
the surface of PNGase F treated cells compared to the untreated control (Figure 1C). However,
surfacePNGase
of PNGase
F treated cells
compareddid
tonot
thesignificantly
untreated control
(Figure
1C).within
However,
PNGase F
F pre-treatment
of monolayers
affect the
GAS CFU
the biofilms
pre-treatment
of monolayers did not significantly affect the GAS CFU within the biofilms (Figure 1D).
(Figure 1D).
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Figure 1. Indiscriminate removal of N-linked glycans from the pharyngeal cell surface via PNGase F
(D) biomass. (A) Assay schematic
treatment results in increased(C)
M12 Group A Streptococcus (GAS) biofilm
for 72 h M12 GAS biofilms formed on PNGase F pre-treated and untreated pharyngeal monolayers.
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Untreated and PNGase F pre-treated Detroit 562 pharyngeal monolayers (without biofilm) were
also imaged as controls to ensure that PNGase F treatment did not affect pharyngeal cell morphology
(Figure 2B,D).
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and
the
the previously described importance of sialic acid in bacterial virulence, the role of these structures
previously described importance of sialic acid in bacterial virulence, the role of these structures in GAS
in GAS biofilm formation was further explored.
biofilm formation was further explored.
To do so, Detroit 562 pharyngeal monolayers were first pre-treated with specific
To do so, Detroit 562 pharyngeal monolayers were first pre-treated with specific exoglycosidases; α1-6
exoglycosidases; α1-6 mannosidase (removes α1-6 linked mannose residues), α1-2,3 mannosidase
mannosidase (removes α1-6 linked mannose residues), α1-2,3 mannosidase (removes α1-2 and α1-3 linked
(removes α1-2 and α1-3 linked mannose residues), and the broad specificity sialidase (which will be
mannose residues), and the broad specificity sialidase (which will be referred to as Sialidase A) (removes
referred to as Sialidase A) (removes linear and branched terminal α2-3, α2-6, α2-8, and α2-9 linked
linear and branched terminal α2-3, α2-6, α2-8, and α2-9 linked sialic acid); and monosaccharide removal
sialic acid); and monosaccharide removal was confirmed by lectin binding assays (see Supplementary
was confirmed by lectin binding assays (see Supplementary Material, Figure S2). Initial adherence of
Material, Figure S2). Initial adherence of planktonic GAS after 2 h incubation with the untreated and
planktonic GAS after 2 h incubation with the untreated and exoglycosidase pre-treated monolayers was
exoglycosidase pre-treated monolayers was determined. The biofilms formed on these monolayers
determined.
Thefor
biofilms
these
monolayers
assessed
biofilm
were assessed
biofilmformed
biomassonand
bacterial
colonywere
forming
unitsfor
(Figure
4A)biomass and bacterial
colonyInvestigation
forming unitsinto
(Figure
4A).
the initial adherence of planktonic M12 GAS interacting with the
Investigationpre-treated
into the initial
of planktonic
M12 no
GAS
interacting
with the exoglycosidase
exoglycosidase
andadherence
control monolayers
found
significant
differences
(Figure 4B).
pre-treated
and
control
monolayers
found
no
significant
differences
(Figure
4B).
Despite
this, thepre72 h
Despite this, the 72 h M12 GAS biofilms exhibited increased biomass on the exoglycosidase
M12
GAS
biofilms
exhibited
increased
biomass
on
the
exoglycosidase
pre-treated
monolayers
compared
treated monolayers compared to the untreated control (Figure 4C). Notably, α1-6 mannosidase and
toSialidase
the untreated
control (Figure
4C). Notably,
α1-6
mannosidase
and (p
Sialidase
pre-treatment
A pre-treatment
of monolayers
resulted
in significant
increases
≤ 0.05) inAbiofilm
biomass.of
monolayers
in significant
increases
(p the
≤ 0.05)
in biofilm
biomass.
The number between
of colony
The numberresulted
of colony
forming units
within
biofilms
did not
differ significantly
forming
units
within
the
biofilms
did
not
differ
significantly
between
treatments
(Figure
4D).
treatments (Figure 4D).
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Investigation into the initial adherence of planktonic M12 GAS interacting with the exoglycosidase
Figure 4.
4. Pre-treatment
Pre-treatment of
and
Sialidase
AA
results
in in
Figure
of pharyngeal
pharyngealcell
cellsurface
surfacewith
withα1-6
α1-6mannosidase
mannosidase
and
Sialidase
results
pre-treated and
control
monolayers
found
no
significant
differences
(Figure
4B).
Despite
this, the 72 h
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increased M12
forfor
the
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of of
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M12 GAS
GAS biofilm
biofilm biomass.
biomass.(A)
(A)Assay
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schematic
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and
Sialidase
biofilms
formed
on each
each
of the
theexoglycosidase
exoglycosidase
(α1-6
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α1-2,3
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and
Sialidase compared
A) pre-treated
vs.
Initial
adherence
enumerated
forfor
planktonic
to the untreated
controlpharyngeal
(Figuremonolayers
4C). Notably,
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and
Sialidase
A pre-treatment of
(A)
pre-treated
pharyngeal
monolayers
vs.untreated.
untreated.
(B)
Initial
adherence
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planktonic
GAS
upon
2
h
incubation.
72
h
biofilms
are
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for
(C)
biofilm
biomass
via
crystal
violet
staining
upon 2 in
h incubation.
72 h biofilms
are assessed
for (C)in
biofilm
biomass
via crystal violet
monolayers GAS
resulted
significant
increases
(p ≤ 0.05)
biofilm
biomass.
The staining
number of colony
and (D)
(D) colony
colony forming
forming units
SEM,
with
statistical
analysis
and
units via
via enumeration.
enumeration.Data
Datarepresents
representsmean
mean± ±
SEM,
with
statistical
analysis
forming unitsperformed
within using
the biofilms
not differ
significantly
between test
treatments
a one-waydid
ANOVA
with Tukey’s
multiple comparisons
* (p ≤ 0.05);(Figure
n = 3 4D).
performed using a one-way ANOVA with Tukey’s multiple comparisons test * (p ≤ 0.05); n = 3 biological
biological replicates,
with 3replicates
technical replicates
each.
replicates,
with 3 technical
each.

2.3.2. Biofilm EPS

2.3.2. Biofilm EPS
2.3.2.

Biofilms are comprised of bacterial cells and EPS. To further determine what may be contributing
Biofilms are
arecomprised
comprised
of bacterial
and To
EPS.
To further
determine
may be
Biofilms
of bacterial
cellscells
and EPS.
further
determine
what maywhat
be contributing
to the observed
changes
in
biofilm
biomass,
EPS
associated
sulphated
GAGs,
extracellular
DNA
contributing
to changes
the observed
changes
in biofilm
biomass, sulphated
EPS associated
GAGs,
to
the observed
in biofilm
biomass,
EPS associated
GAGs,sulphated
extracellular
DNA
(eDNA),(eDNA),
and protein
was(eDNA),
assessed
5A).
extracellular
and (Figure
protein
was
assessed (Figure 5A).
and DNA
protein
was assessed
(Figure
5A).
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1,9 dimethyl methylene blue (DMMB) staining was used to detect EPS-associated sulphated
GAGs [33,34]. EPS associated sulphated GAGs increased significantly for M12 GAS biofilms formed
on α1-6 mannosidase (p ≤ 0.01) and Sialidase A (p ≤ 0.05) pre-treated pharyngeal cell monolayers
compared to the untreated control (Figure 5B). This result supports the findings from crystal violet
staining, suggesting EPS production increases in response to modification of cell surface glycans.
Lastly, EPS was examined for common EPS components (eDNA and protein), via fluorescent stains
Sytox Blue and SYPRO Ruby (Figure 5C). There were no significant differences in the presence of EPS
associated eDNA or protein in biofilms formed.
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formed
α1-6
mannosidase
Sialidase
A
Figure 5. Biofilm
EPS
increases
significantly
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biofilms
formed
on
α1-6
mannosidase
and Sialidase
A
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pre-treated
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(α1-6 mannosidase,
and
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formed
on
each
of
the
exoglycosidase
(α1-6
mannosidase,
α1-2,3
mannosidase,
and
Sialidase
A)
pre-treated
pharyngeal
monolayers
vs.
untreated.
72
h
biofilms
were
assessed
for
(B)
Sialidase A) pre-treated pharyngeal monolayers vs. untreated. 72 h biofilms were assessed for (B) EPS and
EPS
via DMMB
staining
of sulphated
GAGs
and
(C)EPS
EPSassociated
associated72
components
(eDNA
protein)
Sialidase A)
pre-treated
pharyngeal
monolayers
vs.
untreated.
h biofilms
wereand
assessed
for
via
DMMB
staining
of sulphated
GAGs
and
(C)
components
(eDNA
and
protein)
via(B) EPS
via fluorescent staining with Sytox Blue and FilmTracer SYPRO Ruby biofilm matrix stain,
with Sytox
Blueand
and (C)
FilmTracer
SYPRO Ruby
biofilm matrix
stain, respectively.
via DMMBfluorescent
staining staining
of sulphated
GAGs
EPS associated
components
(eDNA
and protein) via
respectively. Data represents mean ± SEM, with statistical analysis performed using a one-way
Data
represents
mean
±
SEM,
with
statistical
analysis
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using
a
one-way
ANOVA
with
fluorescentANOVA
staining
with
Sytox
Blue
and FilmTracer
SYPRO
biofilm
matrixreplicates,
stain,Tukey’s
respectively.
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Tukey’s
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(p ≤ 0.01);
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multiple comparisons test * (p ≤ 0.05) and ** (p ≤ 0.01); n = 3 biological replicates, with 3 technical
Data represents
± SEM,
with
statistical analysis performed using a one-way ANOVA with Tukey’s
with 3mean
technical
replicates
each.
replicates each.
multiple comparisons test * (p ≤ 0.05) and ** (p ≤ 0.01); n = 3 biological replicates, with 3 technical
To visually investigate the effect of exoglycosidase (α1-6 mannosidase, α1-2,3 mannosidase, and
1,9 dimethyl methylene blue (DMMB) staining was used to detect EPS-associated sulphated
replicates each.

Sialidase A) pre-treated pharyngeal monolayers on M12 GAS biofilm formation, SEM imaging was

GAGs [33,34]. EPS associated sulphated GAGs increased significantly for M12 GAS biofilms formed
conducted (Figure 6). Biofilms formed on both untreated and exoglycosidase pre-treated monolayers
on
α1-6 mannosidase (p ≤ 0.01) and Sialidase A (p ≤ 0.05) pre-treated pharyngeal cell monolayers
show M12 GAS chained cocci arranged into three dimensional aggregated structures with EPS matrix
compared
to the untreated
control (Figure
5B).
This result
supports
findings from
crystal violet
material present
(Figure 6A,C,E,G).
Biofilms
formed
on each
of the the
exoglycosidase
pre-treated
staining,
suggesting
EPS
production
increases
in
response
to
modification
of
cell
surface
glycans.
pharyngeal monolayers appear to produce more EPS matrix material associated with the aggregated
Lastly,
EPS
was
examined
for
common
EPS
components
(eDNA
and
protein),
via
fluorescent
GAS cocci when compared to GAS biofilm formed on the untreated control. EPS produced on allstains
Sytox Blue and SYPRO Ruby (Figure 5C). There were no significant differences in the presence of EPS
associated eDNA or protein in biofilms formed.
To visually investigate the effect of exoglycosidase (α1-6 mannosidase, α1-2,3 mannosidase, and
Sialidase A) pre-treated pharyngeal monolayers on M12 GAS biofilm formation, SEM imaging was
conducted (Figure 6). Biofilms formed on both untreated and exoglycosidase pre-treated monolayers
show M12 GAS chained cocci arranged into three dimensional aggregated structures with EPS
matrix material present (Figure 6A,C,E,G). Biofilms formed on each of the exoglycosidase pre-treated
pharyngeal monolayers appear to produce more EPS matrix material associated with the aggregated
GAS cocci when compared to GAS biofilm formed on the untreated control. EPS produced on all GAS
biofilms display the distinct forms seen previously, a web-like mesh matrix (small black arrows) and a
more globular matrix (big black arrows). Both extend from the cocci cell surface of these biofilm cells.
Untreated and exoglycosidase pre-treated Detroit 562 pharyngeal monolayers (without biofilm) were
also imaged as controls to ensure that each exoglycosidase treatment did not affect pharyngeal cell
morphology/structures (Figure 6B,D,F,H).

GAS biofilms display the distinct forms seen previously, a web-like mesh matrix (small black arrows)
and a more globular matrix (big black arrows). Both extend from the cocci cell surface of these biofilm
cells. Untreated and exoglycosidase pre-treated Detroit 562 pharyngeal monolayers (without biofilm)
were also imaged as controls to ensure that each exoglycosidase treatment did not affect pharyngeal
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cell morphology/structures (Figure 6B,D,F,H).
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pharyngeal
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562 pharyngeal
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and
DetroitBiofilms
562 pharyngeal
cell 562
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biofilm) were
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usingwere
the JEOL
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respectively.
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were
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and
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and
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two
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with
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represent two biological replicates with two technical replicates each.
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IncreasedBiofilm
BiofilmFormation
Formation Promotes
Promotes Penicillin
Penicillin Tolerance
Tolerance
Penicillin
thethe
antibiotic
of choice
for the
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infections
[35]. The [35].
biofilm
phenotype
Penicillinisis
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of choice
fortreatment
the treatment
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known to decrease
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is suspected
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is knownbacterial
to decrease
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to antibiotics
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antibiotic
failure of
rate
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of GAS
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[2–4].
As such,
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treatment
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rate of 20–40%
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[2–4]. Ascases
such,
the penicillin
the penicillinof
susceptibility
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Firstly,the
the susceptibility
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penicillin
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the
Firstly,
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the
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inhibitory
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(MIC)
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the
(data
shown).
AA
MIC
andand
MBC
of 0.025
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whichwhich
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with thewith
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reported
GAS
MIC
and
MBC
range
for
penicillin
[36,37].
Notably,
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biofilm
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GAS MIC and MBC range for penicillin [36,37]. Notably, minimum biofilm eradication concentration
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forformed
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formed
on untreated
and
values
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on untreated
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penicillinformed
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Specifically,
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on untreated
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formed
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untreated
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Table 1.
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exhibit enhanced
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when
formed upon
Table
biofilms
exhibit enhanced
penicillin
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treated
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MBECs
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for
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M12
GAS
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MBEC
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2500
Untreated
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2500
α1-6 mannosidase
125
5000
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125
5000
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5000
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5000
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2.5. Targeted Removal of Glycans from Pharyngeal Monolayers Affects Biofilm Formation by GAS emm-types in
2.5.a Targeted
Removal
of Glycans from
Pharyngeal Monolayers Affects Biofilm Formation by GAS emmboth
Glycan- and
Strain-Dependent
Manner
types in both a Glycan- and Strain-Dependent Manner
The enzymatic removal of terminal mannose and sialic acid residues from the pharyngeal cell
enzymatic
removal of
terminalinmannose
and
sialic biomass.
acid residues
from the
pharyngeal
surfaceThe
resulted
in significant
increases
M12 GAS
biofilm
To assess
if this
is the casecell
for
surface
resulted
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in M12 on
GAS
biofilm
biomass. was
To assess
if this is for
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for
other
GAS
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effect of increases
glycan removal
biofilm
formation
investigated
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other GAS
strains,
theisolates.
effect of glycan removal on biofilm formation was investigated for a diverse
selection
of eight
GAS
selection
of
eight
GAS
isolates.
Assessed GAS M-types (Figure 7) displayed different biofilm forming capacities on the untreated
Assessed GAS
M-typespharyngeal
(Figure 7)monolayers.
displayed different
biofilm forming
capacities
on the
and exoglycosidase
pre-treated
With the exception
of M53, all
isolates exhibited
untreated and exoglycosidase pre-treated pharyngeal monolayers. With the exception of M53, all
a trend of significantly increased biofilm biomass when grown on at least one of the exoglycosidase
isolates exhibited a trend of significantly increased biofilm biomass when grown on at least one of
pre-treated pharyngeal monolayers. M9, M44, and M90 all displayed significant increases in biofilm
the exoglycosidase pre-treated pharyngeal monolayers. M9, M44, and M90 all displayed significant
biomass when grown on all three exoglycosidase pre-treated pharyngeal monolayers. Interestingly,
increases in biofilm biomass when grown on all three exoglycosidase pre-treated pharyngeal
these three M-types all belong to the same emm pattern (pattern E). However, no unifying trends
monolayers. Interestingly, these three M-types all belong to the same emm pattern (pattern E).
were found when comparing GAS emm-types belonging to pattern A–C (M1, 3, and 12) or pattern
However, no unifying trends were found when comparing GAS emm-types belonging to pattern A–
D (M53, 98, and 108). Overall, significant increases in biofilm biomass were both strain and terminal
C (M1, 3, and 12) or pattern D (M53, 98, and 108). Overall, significant increases in biofilm biomass
glycan (mannose/sialic acid residue) dependent.
were both strain and terminal glycan (mannose/sialic acid residue) dependent.

GAS M-types

Figure 7. Assessment of the effect exoglycosidase treated pharyngeal cell monolayers exert on biofilms
Figure 7. Assessment of the effect exoglycosidase treated pharyngeal cell monolayers exert on
of eight other GAS M-types. Biofilm biomass was quantified via crystal violet staining. Data represents
biofilms of eight other GAS M-types. Biofilm biomass was quantified via crystal violet staining. Data
mean ± SEM, with statistical analysis performed using a one-way ANOVA with Tukey’s multiple
represents mean ± SEM, with statistical analysis performed using a one-way ANOVA with Tukey’s
comparisons test, * (p ≤ 0.05), ** (p ≤ 0.01), and *** (p ≤ 0.001); n = 3 biological replicates, with 3 technical
multiple comparisons test, * (p ≤ 0.05), ** (p ≤ 0.01), and *** (p ≤ 0.001); n = 3 biological replicates, with
replicates each.
3 technical replicates each.

3. Discussion and Conclusions
3. Discussion and Conclusions
Pharyngitis is the most prevalent form of GAS disease [1,35]. Although other pathogenic agents
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most
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to
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narrow
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activity,
safety,
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Despite
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GAS
resistance
to
penicillin
to
date
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M12 GAS biofilms displayed a significant increase in biofilm biomass on PNGase F treated cells.
SEM imaging of biofilms formed on both untreated and PNGase F pre-treated monolayers revealed
adherent M12 GAS cocci chains arranged in three dimensional aggregated structures intermeshed with
EPS matrix. Moreover, biofilms formed on PNGase F pre-treated monolayers were seen to have more
EPS matrix. Two varieties of EPS matrix were visible; the globular EPS matrix seen in the current study
is phenotypically similar to GAS biofilms imaged via SEM previously on the surface of tonsils removed
from patients with recurrent GAS tonsillopharyngitis [7]. The web-like EPS matrix projecting from
the cocci cell surface of these biofilms has been captured in one previous study of M2 GAS biofilms,
with the authors describing the EPS matrix material as “threadlike structures of an as-yet unknown
chemical composition” [8].
Although this is an interesting finding, it is unlikely in vivo that a host cell surface would be
lacking in all or most of its N-linked glycans. As such, we focused on the role of specific N-linked
glycans that are abundant on the Detroit 562 pharyngeal cell surface in this study. PGC-LC-ESI-MS/MS
analysis of the Detroit 562 pharyngeal cell surface N-glycome revealed that oligomannose structures
are the most abundant class of N-glycan, followed by complex and hybrid glycans, with mannose
being the predominant monosaccharide on the cell surface. As mannosidases act upon oligomannose
N-glycans primarily, and hybrid N-glycans secondarily, broad-spectrum sialidase treatment was
additionally utilised in this study to act upon complex and hybrid N-glycans. Removal of terminal
mannose and sialic acid residues resulted in an increase of biofilm biomass similar to that induced by
total N-glycan removal with PNGase F, independent of initial adherence and biofilm viability. It is
possible that removal of these glycans enables access by GAS to otherwise impeded host receptors
involved in the host-pathogen interaction, further promoting biofilm formation. The importance of
terminal monosaccharides has been demonstrated in a previous study of GAS binding to human
buccal epithelial (HBE) cells, whereby expression of terminal galactose and sialic acid residues had
significant effects on M1, 3, and 12 associations, whilst terminal fucose and N-acetylgalactosamine
were of comparatively lesser dependence of binding for all three GAS M-types. It was suggested that
fucose and N-acetylgalactosamine may have a host-protective effect, sterically hindering access to the
preferred galactose residues [25]. Many pathogens are known to possess their own suite of glycosidases
which they utilize to liberate glycan residues for their own metabolic processes, and moreover, to better
access preferred glycan structures for adherence [44,45]. For example, S. pneumoniae expresses multiple
neuraminidases that cleave off sialic acids, unmasking other receptors for increased binding and
virulence [44].
Given that initial planktonic GAS adherence and the population of live cells within the biofilms
did not seem to uniquely contribute to the increases in biofilm biomass, EPS was examined. The EPS
is an important component of the biofilm, and it is thought to contribute to around 80–85% of the
total biofilm biomass [46]. The removal of glycans did not result in an increase of initial bacterial
adherence, and it is possible changed glycan structures modified expression of genes associated with
EPS production, although this was not explored in the current study. The EPS matrix has its own
complex and dynamic matrixome, which defines the compositional and functional diversity of the EPS.
EPS is predominantly comprised of polysaccharides, proteins, eDNA, and lipids. Despite variability
in their composition across pathogens, EPS-associated polysaccharides are generally considered the
most abundant [47–49]. Currently, GAS EPS remains poorly defined, with only one study having
investigated EPS polysaccharides, determining that L-glucose and D-mannose were the most abundant
sugar moieties of the EPS of one M6 strain [50].
DMMB staining is a simple approach that has been used extensively in staining the EPS
GAG polysaccharides of numerous other bacterial biofilms (e.g., Staphylococcus aureus, P. aeruginosa,
Burkholderia cenocepacia, and Propionibacterium acnes) [33,34]. Here, for the first time, it is demonstrated
that DMMB is suitable for detecting GAS biofilm EPS-associated GAGs. Moreover, DMMB
staining revealed that biofilms formed on α1-6 mannosidase and Sialidase A pre-treated pharyngeal
monolayers exhibited significantly increased EPS polysaccharide production, despite eDNA or protein
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abundance remaining unchanged. Further assessment of other EPS components such as lipids
and a diverse range of polysaccharides should be investigated via other fluorescent stains such
as 1,10 -dioctadecyl-3,3,30 ,30 -tetramethylindodicarbocyanine perchlorate (DiD’oil) or concanavalin A
conjugated to a fluorophore such as tetramethylrhodamine [51]. SEM imaging of biofilms formed on
both untreated and each of the exoglycosidase pre-treated monolayers revealed biofilms similar to
those seen on untreated and PNGase F pre-treated monolayers. Biofilms show adherent M12 GAS cocci
chains arranged in three dimensional aggregated structures intermeshed with EPS matrix. Similar to
results following PNGase F treatment, biofilms formed on exoglycosidase pre-treated pharyngeal cell
monolayers showed an increase in EPS matrix. Both varieties of EPS (globular and web-like) were
present in biofilms formed.
A critical characteristic of the biofilm phenotype is increased tolerance to antimicrobials,
with reports of antimicrobial tolerance anywhere between 10 and >1000 times greater compared
to planktonic form [52–54]. Biofilms may be a contributing factor for the antibiotic treatment failure
rate of 20–40% reported in cases of GAS pharyngitis. Here we determined if the observed increase in
biofilm formation was functionally relevant in the context of penicillin tolerance when compared to
planktonic GAS. Penicillin tolerance doubled following removal of mannose and sialic acid residues,
respectively, from the pharyngeal monolayer substratum. We have shown that removal of these
residues leads to increases in EPS which may have impeded penicillin penetration through the
biofilm. Several other features unique to the biofilm phenotype may have further contributed to the
increase in penicillin tolerance including differential growth rates of bacterial cells, nutrient gradients,
and antibiotic degradation once in the biofilm [55–58]. Further study should aim to characterise the
specific mechanisms for the enhanced penicillin tolerance described here.
The indiscriminate removal of all N-glycans and the targeted removal of terminal mannose
and sialic acid, which predominate the surface of Detroit 562 pharyngeal cells, increases biofilm
biomass, specifically via increased EPS production. Similar results were observed in eight other
clinically relevant GAS emm-types, albeit in a glycan- and strain-dependent manner, suggesting that
the influence of the host glycome on the biofilm phenotype is not limited to a single strain or emm-type.
The presence of certain host glycan structures may be a host-protective mechanism, reducing the
formation of GAS biofilms in vivo. GAS has been shown to modify host glycoproteins via recently
discovered glycosidases endoglycosidase S and α-mannosidase [59,60]. The ability of GAS to modify
the host-glycome at different sites and stages of infection has not been characterised. Our findings
suggest that modification of the host glycome during the course of infection may increase the ability of
GAS to form biofilms.
GAS is commonly attributed to pharyngeal infection with over 600 million cases per year,
presenting a considerable global burden [1]. Recurrent GAS infection, persistent carriage, and antibiotic
treatment failure remain challenging and unresolved, despite numerous efforts in characterising the
consortia of molecular mechanisms underpinning GAS virulence and pathogenesis. Moreover, most of
these studies have been conducted only in the context of planktonic GAS. Here GAS biofilm formation
has been investigated, with a particular focus on the effect of altering pharyngeal cell surface glycans.
Host cell surface glycans may offer a protective advantage against GAS biofilm formation. We have
shown that modulation of the pharyngeal glycome has a direct impact on GAS biofilm formation,
with increases in EPS likely to play an important role. Moreover, the increased GAS biofilms displayed
significantly greater penicillin tolerance dependent on the host cell glycome. This study describes the
effect of host glycosylation on GAS biofilm formation and GAS biofilm formation as an important
proponent in penicillin tolerance.
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4. Materials and Methods
4.1. GAS and Culture Conditions
GAS strains used in this study (see Supplementary Material, Table S2) are clinical GAS isolates,
with each strain representative of a discrete GAS emm-type [25,61–64]. GAS was grown on horse blood
agar (HBA) plates (Edwards, Murarrie, Australia) or Todd Hewitt agar supplemented with 1% (w/v)
yeast (THYA). Static cultures of GAS were grown overnight in Todd Hewitt broth (BD Sparks, MD,
USA) supplemented with 1% (w/v) yeast (THY). GAS was cultured and maintained at 34 ◦ C [65].
4.2. Human Pharyngeal Cell Culture Conditions and Monolayer Formation
Detroit 562, a human pharyngeal epithelial cell line (CellBank Australia, Westmead, Australia),
was cultured in Dulbecco’s Modified Eagle Medium (DMEM) F12 (Gibco, Grand Island, NY, USA),
supplemented with 2 mM L-glutamine (Gibco, Life Technologies, Grand Island, NY, USA) and 10%
(v/v) heat inactivated foetal bovine serum (FBS) (Bovogen Biologicals, Keilor East, Australia) in cell
culture flasks at 37 ◦ C, 5% CO2 to 20% O2 atmosphere.
Fixed Detroit 562 pharyngeal cell monolayers form the substratum for bacterial growth for
subsequent biofilm experiments. In brief, wells of 96-well flat bottom cell culture microtiter plates
(Greiner Bio-One, Frickenhausen, Germany) were coated with 300 µg/mL Collagen I from rat tail
(Gibco, Life Technologies, Grand Island, NY, USA) and incubated for 1 h, 37 ◦ C, 5% CO2 to 20% O2
atmosphere. After 1 h, wells were seeded with 150 µL Detroit 562 cell suspension (2 × 105 cells/mL)
and cultured for 48 h (or until a monolayer of ~95% confluency was achieved). Monolayers were
washed once with PBS and fixed with sterile 3.7% paraformaldehyde for 20 min. Once fixed, wells
were washed twice with PBS, and monolayers were kept wet via submersion in PBS until required
for use.
4.3. Characterisation of Detroit 562 Pharyngeal Cell Surface N-linked Glycans
Cell surface membrane proteins were purified from Detroit 562 culture lysates as previously
described [30]. N-glycans released by PNGase F (Promega, Madison, WI, USA) were purified and
processed, prior to analysis by porous graphitised carbon liquid chromatography coupled with
electrospray ionisation tandem mass spectrometry as described elsewhere [66]. For methods in full,
see Supplementary Material 3.
4.4. Detroit 562 Pharyngeal Cell Monolayer Pre-Treatment
4.4.1. PNGase F Treated Monolayers
Wells of the 96-well microtiter plates containing pre-formed fixed Detroit 562 pharyngeal cell
monolayers were blocked with 1% PVP40 solution and incubated for 5 min. Once blocked, the PVP40
was removed, and the wells washed thrice with water. For the removal of N-linked glycans, 5 µL of
PNGase F (50 U) (Promega, Madison, WI, USA) and 10 µL PBS was added to each well and incubated
overnight at 37 ◦ C. After incubating with PNGase F, released N-linked glycans were removed and the
wells washed once with PBS. Untreated PBS wells representing the whole glycome of the Detroit 562
pharyngeal cell monolayers were also included as a control. N-linked glycan removal was confirmed
via Concanavalin A Alexa fluor 647 lectin binding assay (Supplementary Material, Figure S1). In brief,
untreated and PNGase F pre-treated pharyngeal cell monolayers were incubated with 5 µg/mL
Concanavalin A Alexa fluor 647 (Life technologies, Carlsbad, CA, USA) for 15 min (RT, dark).
Unbound lectin removed, and monolayers washed twice with 100 µL PBS. Untreated and PNGase F
pre-treated monolayers incubated without lectin (PBS) served as background/auto-fluorescence controls
and were subtracted from sample reads. Samples were read spectrofluorometrically at excitation
625–30 nm/emission 680–30 nm.
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4.4.2. Exoglycosidase: α1-6 Mannosidase, α1-2, 3 Mannosidase, and Sialidase A Treated Monolayers
Pre-formed fixed Detroit 562 pharyngeal cell monolayers of the 96-well microtiter plate were
treated with 30 µL/well reaction volumes of each of the exoglycosidases. For mannosidases, the reaction
volume comprises 3 µL 1 × GlycoBuffer 1 (NEB, Notting Hill, Australia), 0.3 µL 100 µg/mL purified
BSA (NEB, Notting Hill, Australia), 0.2 µL α1-6 mannosidase (8 U) or α1-2,3 mannosidase (8 U)
(NEB, Notting Hill, Australia), and 26.5 µL PBS. For Sialidase A, 6 µL 5 × Reaction Buffer B (250 mM
sodium phosphate pH 6.0) (Prozyme, Hayward, CA, USA), 0.2 µL Sialidase A (1 × 10−3 U) (Prozyme,
Hayward, CA, USA), and 23.8 µL PBS. Untreated PBS wells representing the intact surface glycome
of the fixed Detroit 562 pharyngeal cell monolayers were also included as a control. The plate was
incubated for 2 h, 37 ◦ C. Once incubated, the wells were washed once with PBS. Glycan removal
was confirmed via lectin binding assay as per [25], with exoglycosidase pre-treated pharyngeal cell
monolayers incubated with either biotinylated Hippeastrum hybrid lectin (binding mannose residues)
(Vector Laboratories, Burlingame, CA, USA) or biotinylated Sambucus nigra lectin (binding sialic acid
residues) (Vector Laboratories, Burlingame, CA, USA) (Supplementary Material 5, Figure S2).
4.5. Initial Adherence of Planktonic GAS
Pre-formed fixed Detroit 562 pharyngeal cell monolayers were inoculated with 150 µL of stationary
phase GAS culture diluted 1:20 in THY (v/v) supplemented with sterile 0.5% glucose (THY-G) and
incubated for 2 h to promote initial attachment (34 ◦ C, slow shaking at 50 rpm). At 2 h, non-adherent
GAS was removed, and the wells washed thrice with PBS. To detach Detroit 562 cells from the
bottom of the microtiter plate, 0.05% trypsin-EDTA (1×) (Gibco, Grand Island, NY, USA) was added
to each well and incubated (15 min, 37 ◦ C). To lyse the now-detached Detroit 562 cells containing
internalised bacteria, 0.025% Triton X-100 was added and pipetted vigorously. To enumerate the
adherent GAS population, 10-fold serial dilutions of the cell suspensions were performed in PBS and
aliquots spot plated onto THYA (incubated overnight, 34 ◦ C) for subsequent colony counting and
CFU/mL determination.
4.6. GAS Biofilm
96-well microtiter plates containing pre-formed fixed Detroit 562 pharyngeal cell monolayers
untreated and pre-treated with either PNGase F or the exoglycosidases were inoculated with 150 µL
of overnight GAS culture diluted 1:20 in THY-G. The inoculum was incubated for 2 h (34 ◦ C, 50 rpm).
At 2 h, non-adherent GAS was removed, and wells replenished with sterile THY-G. Subsequent 72 h GAS
biofilms were produced (34 ◦ C, 50 rpm), with sterile THY-G media refreshment performed every 24 h.
4.6.1. GAS Biofilm Biomass Crystal Violet Staining
Biofilm biomass was assessed via crystal violet (CV) staining. Biofilms were air dried for 30 min
(or until completely dried), and fixed with 99% methanol for 15 min. Once fixed, the biofilms were
thoroughly air-dried and stained with 0.2% CV (w/v) (Sigma-Aldrich, St Louis, MO, USA) supplemented
with 1.9% ethanol (v/v) for 10 min (RT, static). Once stained, excess CV was removed and each well
gently washed twice with PBS. CV stain that had incorporated into the biofilm was re-solubilised in
1% sodium dodecyl sulphate (SDS) (w/v) (Sigma-Aldrich, St Louis, MO, USA), and incubated (10 min,
RT). Monolayers with THY-G (no GAS biofilm) served as media sterility controls and background
staining controls, with absorbance values subtracted from those of biofilm samples. Biofilm biomass
quantification was performed by diluting the released dye 1:5 in the 1% SDS solution, and subsequently
measured at OD540nm using a SpectraMax Plus 384 microplate reader.
4.6.2. Enumeration of Live Cells within GAS Biofilm
GAS biofilms were assessed for the live cell populations via enumeration of serially diluted
biofilms. Briefly, biofilms were washed once in PBS and thoroughly re-suspended in fresh PBS via

Antibiotics 2020, 9, 775

17 of 22

vigorous scraping of biofilms from the well surface, followed by a 5 min sonication. The population of
live cells within these biofilms were enumerated via 10-fold serially diluting in PBS, and spot plating
onto THYA (incubated overnight, 34 ◦ C) for subsequent colony counting and CFU/mL determination.
4.6.3. GAS Biofilm EPS
To assess biofilm EPS, the (i) EPS-GAGs and (ii) common EPS components (eDNA and protein)
were examined. Briefly, EPS associated GAGs were quantified by 1,9-dimethyl methylene blue (DMMB)
dye based EPS assay adapted from methods described elsewhere [33]. EPS components (eDNA and
protein) were fluorescently stained with Sytox Blue, a cell membrane-impermeant nucleic acid stain
(Molecular Probes, Invitrogen, Eugene, OR, USA) and FilmTracer SYPRO Ruby biofilm matrix stain that
labels most classes of proteins (Molecular Probes, Invitrogen, Eugene, OR, USA). In brief, biofilms were
fixed with 99% methanol for 15 min, and subsequently air dried. Biofilms were individually stained
for 30 min in the dark with 5 µM Sytox Blue and 0.5× concentration FilmTracer SYPRO Ruby biofilm
matrix stain, with PBS as a control. Fixed Detroit 562 pharyngeal monolayers without biofilm were also
stained and served as controls for background staining, with resultant absorbance values subtracted
from biofilm EPS measurements. Fluorescence was measured using a CLARIOStar (with 6 × 6 matrix
well scanning of the non-homogenous biofilms). Sytox Blue was read with an excitation of 440–15 nm
and emission of 484–20 nm, and FilmTracer SYPRO Ruby biofilm matrix read with an excitation of
450–15 nm and emission of 610–20 nm.
4.7. M12 GAS Penicillin Susceptibility
As per accepted guidelines and standard protocols the MIC and MBC values were determined
for penicillin activity against planktonic M12 GAS [67,68]. Briefly, M12 planktonic GAS suspension
(1 × 106 CFU/mL) was challenged with serially diluted penicillin and incubated (24 h, 34 ◦ C). The MIC
was defined as the lowest concentration of penicillin required to completely inhibit bacterial growth
(indicated by clear wells), and further confirmed by measuring OD600nm using a SpectraMax Plus
384 microplate reader. MBC was defined as the lowest concentration of penicillin required to induce
complete killing of bacteria as determined upon spot plating on THYA. For biofilm susceptibility,
MBEC was determined by challenging the pre-formed biofilms with 2-fold dilutions of penicillin in
THY, 2% G (v/v) (24 h, 34 ◦ C). Biofilms were washed once in PBS and thoroughly re-suspended in fresh
PBS. Viable cells were enumerated via 10-fold serially diluting in PBS, and spot plating onto THYA
(incubated overnight, 34 ◦ C) for subsequent colony counting and CFU/mL determination. The MBEC
was determined as the lowest concentration of penicillin required to induce complete eradication of
GAS biofilm [69].
4.8. Scanning Electron Microscopy
M12 GAS biofilms were grown on untreated and PNGase F or exoglycosidase pre-treated
fixed Detroit 562 pharyngeal monolayers on 13 mm plastic Nunc Thermanox coverslips (Proscitech,
Rochester, NY, USA) in a 12-well polystyrene plate. Biofilms were air dried, and prepared for SEM
using methods adapted from [70] with the following modifications. In brief, biofilms were pre-fixed
in 2.5% glutaraldehyde (Sigma-Aldrich, St Louis, MO, USA), 50 mM L-lysine monohydrochloride,
and 0.001% ruthenium red (Sigma-Aldrich, St Louis, MO, USA) solution prepared in 0.1 M HEPES
buffer (pH 7.3) (30 min, 4 ◦ C). Following pre-fixation, biofilms were fixed in fixative solution (2.5%
glutaraldehyde and 0.001% ruthenium red prepared in 0.1 M HEPES buffer, pH 7.3) for 1.5 h (4 ◦ C)
and washed twice in 0.1 M HEPES buffer. Post-fixation (2 h), 2% osmium tetroxide vapour was used,
followed by three washes with distilled water (each 15 min). A graded ethanol series (30%, 50%, 70%,
90%, and 3 × 100%) was then used to remove all water from the biofilms before they were critical
point dried (Leica CPD 030, Austria). Dried biofilms were then sputter coated with 20 nm platinum
(Edwards Vacuum coater, USA) and visualized using a JEOL JSM-7500 microscope (JEOL, Japan)
at 15,000× magnification. Untreated and PNGase F or exoglycosidase pre-treated fixed Detroit 562
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pharyngeal monolayer controls (without biofilms) were also imaged at 500× magnification. Images
were taken at random positions within the samples by an UOW Electron Microscopy Centre technician
blinded from the study in an effort to reduce bias.
4.9. Statistical Analysis
All statistical analysis was performed using GraphPad Prism (version 8.4.0, GraphPad Software,
USA). A student’s t-test or a one-way ANOVA was performed with a Tukey’s multiple comparisons
post hoc test where relevant. A p-value of ≤ 0.05 was considered significant.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/11/775/s1.
Table S1: Proposed N-glycan structures identified by PGC-LC-ESI-MS/MS following PNGase F treatment of
membrane proteins extracted from Detroit-562 pharyngeal cells. Table S2: GAS strains utilised in this study,
their M-types and clinical source.Method Text 1 S3: Characterisation of the Detroit 562 pharyngeal cell surface
N-linked glycans. Figure S1: Lectin binding assay confirming removal of N-linked glycans via PNGase F treatment
of Detroit 562 pharyngeal cell monolayers. Figure S2: Lectin binding assay confirming removal of terminal
mannose and sialic acid residues via exoglycosidase treatment of Detroit 562 pharyngeal cell monolayers.
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